Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
Jennifer
J
Couzin
D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003111:Colonic Polyps / Q000517:prevention & control; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D004345:Drug Industry; D004335:Drug and Narcotic Control; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000139:chemically induced; D011358:Product Surveillance, Postmarketing; D020521:Stroke / Q000139:chemically induced; D013450:Sulfones; D013927:Thrombosis / Q000139:chemically induced
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib